Pharmaceutical compositions for antihypertensive treatments: a patent review

Bibliography

• Tamargo J, Duarte J, Ruilope LM. New antihypertensive drugs under development. Curr Med Chem 2015;22(3):305-42
   PubMed Web of Science ®Google Scholar
• Dasgupta C, Zhang L. Angiotensin II receptors and drug discovery in cardiovascular disease. Drug Discov Today 2011;16(1-2):22-34
   PubMed Web of Science ®Google Scholar
• World, Health, Organization. A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013. 2013
   Google Scholar
• Gibson M. Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form: CRC Press, 2009
   Google Scholar
• Available from: www.uspto.gov/web/offices/com/sol/foia/comm/pte/5616599.nfd.pdf [Last accessed 23 July 2015]
   Google Scholar
• Available from: www.genericsweb.com/index.php?object_id=1003 [Last accessed 23 July 2015]
   Google Scholar
• Semalty A. Cyclodextrin and phospholipid complexation in solubility and dissolution enhancement: A critical and meta-analysis. Expert Opin Drug Deliv 2014;11(8):1255-72
   PubMed Web of Science ®Google Scholar
• Arias JL. Liposomes in drug delivery: A patent review (2007 - present). Expert Opin Ther Pat 2013;23(11):1399-414
   PubMed Web of Science ®Google Scholar
• Loftsson T, Jarho P, Másson M, Järvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005;2(2):335-51
   PubMedGoogle Scholar
• Chen J, Lu WL, Gu W, et al. Drug-in-cyclodextrin-in-liposomes: A promising delivery system for hydrophobic drugs. Expert Opin Drug Deliv 2014;11(4):565-77
   PubMed Web of Science ®Google Scholar
• Bunjes H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J Pharm Pharmacol 2010;62(11):1637-45
   PubMed Web of Science ®Google Scholar
• Kalinkova GN. Studies of beneficial interactions between active medicaments and excipients in pharmaceutical formulations. Int J Pharm 1999;187(1):1-15
   PubMed Web of Science ®Google Scholar
• Moribe K, Ueda K, Limwikrant W, et al. Nano-sized crystalline drug production by milling technology. Curr Pharm Des 2013;19(35):6246-58
   PubMed Web of Science ®Google Scholar
• Demetzos C. Advanced drug delivery nanosystems: Perspectives and regulatory issues. Adv Exp Med Biol 2015;822:195-8
   PubMed Web of Science ®Google Scholar
• Demetzos C, Pippa N. Advanced drug delivery nanosystems (aDDnSs): A mini-review. Drug Deliv 2014;21(4):250-7
   PubMed Web of Science ®Google Scholar
• Leucuta SE. Selecting oral bioavailability enhancing formulations during drug discovery and development. Expert Opin Drug Discov 2014;9(2):139-50
   PubMed Web of Science ®Google Scholar
• Smart AL, Gaisford S, Basit AW. Oral peptide and protein delivery: Intestinal obstacles and commercial prospects. Expert Opin Drug Deliv 2014;11(8):1323-35
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat Rev Drug Discov 2014;13(9):655-72
   PubMed Web of Science ®Google Scholar
• Perumal O, Murthy SN, Kalia YN. Turning theory into practice: The development of modern transdermal drug delivery systems and future trends. Skin Pharmacol Physiol 2013;26(4-6):331-42
   PubMed Web of Science ®Google Scholar
• Cardinal JR, James JL, Melsopp E, Oakley DM. Extended-Release Pharmaceutical Formulations. US0159001; 2010
   Google Scholar
• Madan S, Rathinasabapathy V, Arora VK. Orally disintegrating compositions comprising antihypertensive agents. WO146551; 2010
   Google Scholar
• Millan RDS, Dos Santos RAS, Frezard FJG, De Paula WX. Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications. US0164341; 2013
   Google Scholar
• Ruilope LM. Telmisartan for the management of patients at high cardiovascular risk. Curr Med Res Opin 2011;27(8):1673-82
   PubMed Web of Science ®Google Scholar
• The Top 50 Drugs of 2014. C&EN Supplement 2014:39-42
   Google Scholar
• Available from: www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219.htm.04/01/2009 [Last accessed 29 May 2015]
   Google Scholar
• Kothawade SN, Kadam NR, Aragade PD, Baheti DG. Formulation and characterization of telmisatan solid dispersions. Int J PharmTech Res 2010;2(1):341-7
   Google Scholar
• Patel B, Parikh RH, Swarnkar D. Enhancement of dissolution of Telmisartan through use of solid dispersion technique surface solid dispersion. J Pharm Bioallied Sci 2012;4(Suppl):64-8
   Google Scholar
• Zhang Y, Jiang T, Zhang Q, Wang S. Inclusion of telmisartan in mesocellular foam nanoparticles: Drug loading and release property. Eur J Pharm Biopharm 2010;76(1):17-23
   PubMed Web of Science ®Google Scholar
• Patel J, Dhingani A, Garala K, et al. Design and development of solid nanoparticulate dosage forms of telmisartan for bioavailability enhancement by integration of experimental design and principal component analysis. Powder Technol 2014;258:331-43
   Web of Science ®Google Scholar
• Dixit AR, Rajput SJ, Patel SG. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech 2010;11(1):314-21
   PubMed Web of Science ®Google Scholar
• Rizwan M, Aqil M, Ahad A, et al. Transdermal delivery of valsartan: I. Effect of various terpenes. Drug Dev Ind Pharm 2008;34(6):618-26
   PubMed Web of Science ®Google Scholar
• Nishida N, Taniyama K, Sawabe T, Manome Y. Development and evaluation of a monolithic drug-in-adhesive patch for valsartan. Int J Pharm 2010;402(1–2):103-9
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, et al. Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: Statistical optimization, characterization and pharmacokinetic assessment. Int J Pharm 2013;443(1–2):26-38
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, et al. Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan. Nanomedicine 2012;8(2):237-49
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Ali A. Investigation of antihypertensive activity of carbopol valsartan transdermal gel containing 1,8-cineole. Int J Biol Macromol 2014;64:144-9
   PubMed Web of Science ®Google Scholar
• Ahad A, Aqil M, Kohli K, et al. Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: Preclinical assessment of pharmacokinetics in Wistar albino rats. Expert Opin Drug Deliv 2014;11(8):1149-62
   PubMed Web of Science ®Google Scholar
• Poudel BK, Marasini N, Tran TH, et al. Formulation, characterization and optimization of valsartan self-microemulsifying drug delivery system using statistical design of experiment. Chem Pharm Bull 2012;60(11):1409-18
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR. Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan. J Microencaps 2012;29(2):103-14
   PubMed Web of Science ®Google Scholar
• Júlio TA, Zâmara IF, Garcia JS, Trevisan MG. Compatibility and stability of valsartan in a solid pharmaceutical formulation. Braz J Pharm Sci 2013;49(4):645-51
   Web of Science ®Google Scholar
• Schlinger R, Avramoff A. Process for forming solid oral dosage forms of Angiotensin II receptor antagonists. US0278909; 2010
   Google Scholar
• Raghad AN, Hind EZ. Enhancement of candesartan cilexetil dissolution rate by using different methods. Asian J Pharm Clin Res 2015;8(1):320-6
   Google Scholar
• Abdul Hasan Sathali A, Deepa C. Formulation of liquisolid tablets of candesartan cilexetil. Int J Res Pharm Sci 2013;4(2):238-49
   Google Scholar
• Sezgin-Bayindir Z, Antep MN, Yuksel N. Development and Characterization of Mixed Niosomes for Oral Delivery Using Candesartan Cilexetil as a Model Poorly Water-Soluble Drug. AAPS PharmSciTech 2014;16(1):108-17
   PubMed Web of Science ®Google Scholar
• Jasim AM, Ghareeb MM. Preparation and characterization of orodispersible tablets of candesartan cilexetil by direct compression method. Int J Pharm Pharm Sci 2013;5(Suppl 1):328-33
   Google Scholar
• Kumar L, Meel RK, Godara A, et al. Formulation and evaluation of rapid disintegrating tablet of candesartan cilexetil for the management of hypertension. J Chem Pharm Res 2014;6(8):421-8
   Google Scholar
• Zhang Z, Gao F, Bu H, et al. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: In vitro characteristics and absorption mechanism in rats. Nanomedicine 2012;8(5):740-7
   PubMed Web of Science ®Google Scholar
• Sayyad FJ, Tulsankar SL, Kolap UB. Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution. J Pharm Res 2013;7(5):381-8
   Google Scholar
• Gorain B, Choudhury H, Kundu A, et al. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats. Colloids Surf B Biointerfaces 2014;115:286-94
   PubMed Web of Science ®Google Scholar
• Fujisaki Y, Yoshii R, Takaki S. Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation. US0156829; 2013
   Google Scholar
• Ausekar GD, Shivdavkar RB, Godbole HM, et al. Novel method to obtain olmesartan medoxomil with reduced particle size. WO030082; 2014
   Google Scholar
• Kshirsagar R, Patil J, Karwa V. Micronized particles of olmesartan medoxomil and pharmaceutical composition thereof. WO002011; 2014
   Google Scholar
• Trehan A, Gupta S, Batra V, et al. Stable pharmaceutical composition comprising azilsartan medoxomil. WO102628; 2014
   Google Scholar
• Lei X, Peng J, Wang T, et al. Crystalline forms of azilsartan and preparation and uses thereof. WO044816; 2013
   Google Scholar
• Pan B, Huang L, Yang B. Organic amine salts of azilsartan, preparation method and use thereof. US0296334; 2013
   Google Scholar
• Aifeng L, Baohai Y. Azilsartan organic amine salts, preparation method and use thereof. US0238606; 2012
   Google Scholar
• Castan C, Guimberteau F, Meyrueix R, Soula G. Multimicroparticulate Oral Pharmaceutical Form with Modified Release of Angiotensin II Receptor Antagonists. US0311315; 2009
   Google Scholar
• Rajewski LG, Rajewski RA, Heppert K, et al. Enalapril compositions. WO055667; 2014
   Google Scholar
• Cifter Ü, Türkyilmaz A, Yelken G. Stable aliskiren formulations. US0236473; 2011
   Google Scholar
• Cifter Ü, Yelken G, Türkyilmaz A. Multicoated Aliskiren formulations. US0236473; 2011
   Google Scholar
• Paetz J, Muskulus F. Directly pressed aliskiren tablets. US0165235; 2011
   Google Scholar
• Finkelstein N, Finkelstein B, Mittelman A, Koltai T. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof. US0029083; 2012
   Google Scholar
• Gidwani RM, Hiremath C, Striegel HG. Salts of aliskiren. WO098258; 2011
   Google Scholar
• Badone D, Lau CK, Jiandong Y. Aliskiren hemifumarate, crystal form and amorphous solid. WO007725; 2013
   Google Scholar
• Chalikwar SS, Belgamwar VS, Talele VR, et al. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids Surf B Biointerfaces 2012;97:109-16
   PubMed Web of Science ®Google Scholar
• Macdonald RL, Davis CR, Burton K, et al. Polymorph compositions, methods of making, and uses thereof. WO2013169979; 2014
   Google Scholar
• Prisant LM, Elliott WJ. Drug delivery systems for treatment of systemic hypertension. Clin Pharmacokinet 2003;42(11):931-40
   PubMed Web of Science ®Google Scholar
• Christensen HR, Antonsen K, Simonsen K, et al. Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: Half-life shorter than expected? Pharmacol Toxicol 2000;86(4):178-82
   PubMedGoogle Scholar
• Verger MLL, Fluckiger L, Kim YI, et al. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 1998;46(2):137-43
   PubMed Web of Science ®Google Scholar
• Tran TTD, Tran PHL, Choi HG, et al. The roles of acidifiers in solid dispersions and physical mixtures. Int J Pharm 2010;384(1-2):60-6
   PubMed Web of Science ®Google Scholar
• Malaterre V, Ogorka J, Loggia N, Gurny R. Approach to design push-pull osmotic pumps. Int J Pharm 2009;376(1-2):56-62
   PubMed Web of Science ®Google Scholar
• Bobbala SKR, Veerareddy PR. Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. J Liposome Res 2012;22(4):285-94
   PubMed Web of Science ®Google Scholar
• Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58(3):173-82
   PubMed Web of Science ®Google Scholar
• Yadav P, Yadav E, Verma A, Amin S. In vitro characterization and pharmacodynamic evaluation of furosemide loaded self nano emulsifying drug delivery systems (SNEDDS). Journal of Pharmaceutical Investigation 2014;44(6):443-53
   Google Scholar
• Bilgic M. Pharmaceutical composition comprising eplerenone. WO050539; 2012
   Google Scholar
• Deshmukh VP, Khachane VS, Chaudhari GN, Bhamre NB. Pharmaceutical compositions of eplerenone. WO012960; 2007
   Google Scholar
• Del Soldato P, Benedini F, Ongini E. Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive. US0072854; 2007
   Google Scholar
• Tapas A, Kawtikwar P, Sakarkar D. An improvement in physicochemical properties of carvedilol through spherically agglomerated solid dispersions with PVP K30. Acta Poloniae Pharmaceutica - Drug Research 2012;69(2):299-308
   PubMed Web of Science ®Google Scholar
• Friedl T, Schepky G. Bilayer Pharmaceutical Tablet Comprising Telmisartan and a Diuretic and Preparation Thereof. US0309307; 2013
   Google Scholar
• Palaparthi UD, Rout A, Arumalla MR. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide. WO058950; 2009
   Google Scholar
• Beso A, Legen I, Reven S. Pharmaceutical composition. US0134247; 2014
   Google Scholar
• Schumacher HE, Riedel A, Boehm P. Telmisartan and hydrochlorothiazide combination therapy. US0189281; 2011
   Google Scholar
• Murpani D, Raheja P. Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation. WO067601; 2006
   Google Scholar
• Farsi F. Immediate release pharmaceutical composition of valsartan hydrochlorothiazide. WO098578; 2013
   Google Scholar
• Willmann M. Google Patents. Galenical formulations of organic compounds. US0203679; 2009
   Google Scholar
• Mirajkar S, Sen N. Pharmaceutical compositions. WO068577; 2008
   Google Scholar
• Seshadri RK, Panchanathan VT, Ghati SSS, et al. Compositions pharmaceutiques comportant du ramipril et de l’indapamide. WO124611; 2008
   Google Scholar
• Rucman R, Zupet P. Stable formulation of amorphous perindopril salts, a process for the preparation thereof on industrial scale and use thereof in the treatment of hypertension. WO150245; 2008
   Google Scholar
• Eyjolfsson R. Formulations of quinapril and related ace nhibitors. US0118259; 2005
   Google Scholar
• Mathur R, Manan S, Sethi S. Pharmaceutical compositions of quinapril. US0181055; 2005
   Google Scholar
• Daniel J, Harris M, Hokanson G, Weiss J. Stabilization of quinapril using magnesium oxide. US0106057; 2006
   Google Scholar
• Eyjolfsson R. Formulations of Ramipril. US0234353; 2008
   Google Scholar
• Svete P. Pharmaceutical Composition Comprising Perindopril or Its Salts. US0136578; 2009
   Google Scholar
• Hirayama M, Furuuchi R, Yokoyama T. Antihypertensive agents. US0040005; 2013
   Google Scholar
• Jäkel S, Reuter T, Murfin S, et al. Pyrrolopyrimidines for pharmaceutical compositions. US0105708; 2010
   Google Scholar
• Jadhav GB, Upasani CD. Antihypertensive effect of Silymarin on DOCA salt induced hypertension in unilateral nephrectomized rats. Orient Pharm Exp Med 2011;11(2):101-6
   Google Scholar
• Biedermann D, Vavrikova E, Cvak L, Kren V. Chemistry of silybin. Nat Prod Rep 2014;31(9):1138-57
   PubMed Web of Science ®Google Scholar
• Theodosiou E, Purchartová K, Stamatis H, et al. Bioavailability of silymarin flavonolignans: Drug formulations and biotransformation. Phytochem Rev 2014;13(1):1-18
   Web of Science ®Google Scholar
• Kellici TF, Ntountaniotis D, Leonis G, et al. Investigation of the interactions of silibinin with 2-hydroxypropyl-β-cyclodextrin through biophysical techniques and computational methods. Mol Pharmaceutics 2015;12(3):954-65
   PubMed Web of Science ®Google Scholar
• Laight DW. Nitric oxide therapy for cardiovascular disease. Expert Opin Ther Pat 2001;11(6):999-1005
   Web of Science ®Google Scholar
• Serafim RAM, Primi MC, Trossini GHG, Ferreira EI. Nitric oxide: State of the art in drug design. Curr Med Chem 2012;19(3):386-405
   PubMed Web of Science ®Google Scholar
• Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009;32(10):826-34
   PubMed Web of Science ®Google Scholar
• Almirante N, Del SP, Ongini E. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases. WO011646; 2005
   Google Scholar
• Ali A, Almirante N, Franklin C, et al. Nitroderivatives as angiotensin II receptor antagonists. WO2008076246; 2009
   Google Scholar
• Ali A, Lo MMC, Nargund RP. Nitrooxy derivatives as angiotensin ii receptor antagonists. WO065432; 2010
   Google Scholar
• Kellici TF, Tzakos AG, Mavromoustakos T. Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors. Molecules (Basel, Switzerland) 2015;20(3):3868-97
   PubMed Web of Science ®Google Scholar
• Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Del Rev 2010;62(1):83-99
   PubMed Web of Science ®Google Scholar
• Grenha A, Gomes ME, Rodrigues M, et al. Development of new chitosan/carrageenan nanoparticles for drug delivery applications. J Biomed Mater Res A 2010;92(4):1265-72
   PubMed Web of Science ®Google Scholar
• Li L, Ni R, Shao Y, Mao S. Carrageenan and its applications in drug delivery. Carbohydr Polym 2014;103(1):1-11
   PubMed Web of Science ®Google Scholar
• Baer H, Fuerst T, Renner G, Gottschalk M. Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients. US0045506; 2012
   Google Scholar
• Manku M, Rowe J. Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same. US0093922; 2012
   Google Scholar
• Barranco HG, Luna GMC, Senosiain AH. Oral pharmaceutical composition in the form of microspheres and preparation method. WO027334; 2014
   Google Scholar
• Tong G. Gordagen Pharmaceuticals Pty Ltd. Transmucosal delivery of tocotrienol. WO075135; 2014
   Google Scholar
• Desai D, Phuapradit W, Jain A, et al. Supersaturated stabilized nanoparticles for poorly soluble drugs. WO100403; 2014
   Google Scholar
• Platt D. Boston Therapeutics, Inc. Encapsulation of pharmaceuticals for taste masking in chewable tablets. WO152351; 2014
   Google Scholar
• Zhong Y, Zhang Z. Drexel University. Chelated drug delivery systems. WO152790; 2014
   Google Scholar
• Giles TD, Weber MA, Basile J, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: A randomised, multicentre study. Lancet 2014;383(9932):1889-98
   PubMed Web of Science ®Google Scholar
• Waeber B, Feihl F. Nebivolol and valsartan: Useful treatment for hypertension? Lancet 2014;383(9932):1864-6
   PubMed Web of Science ®Google Scholar
• Plata SCR, Tesson N, Jiménez GC, Vaiana L. Crystalline forms of sartans like telmisartan with beta blockers. EP20120384004; 2013
   Google Scholar
• von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 2014;144(1):41-9
   PubMed Web of Science ®Google Scholar
• Hegde S, Marquess D. Theravance Biopharma R&D Ip, Llc. Dual-acting antihypertensive agents. US0011597; 2015
   Google Scholar
• Fatheree PR, Mckinnell RM. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents. WO090929; 2011
   Google Scholar
• Yang YL, Xue CX, Zhang XT, et al. Antihypertensive pharmaceutical composition. US0263660; 2011
   Google Scholar
• Cieplucha A. A pharmaceutical composition containing candesartan cilexetil and amlodipine. WO097209; 2014
   Google Scholar
• Chung YS, Juhn JH, Jung MY, et al. Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof. WO077968; 2012
   Google Scholar
• Chang HC, Kang BK, Kim JK. Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt. WO147462; 2013
   Google Scholar
• Soldati G, Santus G, Marques RV, et al. Pharmaceutical compositions of antihypertensives. WO050339; 2013
   Google Scholar
• Curdy C, Li S, Becker D, et al. Pharmaceutical combination of aliskiren and valsartan. US0247645; 2010
   Google Scholar
• Schumacher C, Huxley A, Zaugg C, Baltatu O. Pharmaceutical composition using aliskiren and avosentan. US0173919; 2010
   Google Scholar
• Shetty SS, Ksander GM. New combinations. US0204190; 2010
   Google Scholar
• Baron AD, Fineman MS, Beeley NRA. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk. WO011926; 2014
   Google Scholar
• Worcel M, Sabolinski ML. Compositions and methods related to heart failure. US0118294; 2009
   Google Scholar